SHARONBIO

Members of the Exchange are hereby informed that the admission to dealings in securities of Sharon Bio-Medicine Limited shall be withdrawn (delisted) w.e.f. February 20, 2024 pursuant to the Resolution Plan approved by the Hon'ble Mumbai Bench of National Company Law Tribunal (NCLT) under Section 31 of the Insolvency and Bankruptcy Code (IBC), 2016.

SHARONBIO:The Exchange had sought clarification from Sharon Bio-Medicine Limited with respect to announcement dated 27-Feb-2023, regarding fire accident at the Company's manufacturing unit located at M/s Sharon Bio-Medicine Limited, Plot No L6, MIDC Area, Taloja , Panvel, Dist: Raigad, Maharashtra. On basis of above the Company was required to clarify following:�� 1. Insurance amount claimed and realized by the listed entity for the loss/damage; 2. The actual amount of damage caused due to the natural calamity or other force majeure events; 3. Details of steps taken to restore normalcy and the

Intimation regarding successful implementation of the Approved Resolution Plan

The Exchange has sought clarification from Sharon Bio-Medicine Limited for the quarter ended 31-Mar-2023 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results not signed by authorized signatory/ies -2. The company has not submitted the Statement of Modified Opinion or in case of unmodified opinion(s), a declaration to that effect to the Stock Exchange. The response of the Company is awaited.

Members of the Exchange are hereby informed that the trading in equity shares of Sharon Bio-Medicine Limited (ISIN: INE028B01029) shall continue to be suspended pursuant to order dated May 17, 2023 passed by National Company Law Tribunal.

Sharon Bio-Medicine Limited has informed the Exchange about of Newspaper Publication of Audited Financial Results March 31, 2023

Annual Secretrial Compliance Report

Sharon Bio-Medicine Limited has submitted to the Exchange, the financial results for the period ended March 31, 2023.

Sharon Bio-Medicine Limited has informed the Exchange regarding Board meeting held on May 30, 2023.

Sharon Bio-Medicine Limited has informed the Exchange that Record date for the purpose of Delisting of Shares pursuant to NCLT Order dated 17th May 2023 is 09-Jun-2023.

Intimation regarding Monitoring Committee pursuant to the order of NCLT dated 17th May 2023

Intimation about the Approval of Resolution Plan

Intimation regarding Approval of Resolution Plan by Hon'ble NCLT

Sharon Bio-Medicine Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018

In furtherance to our corporate announcement dated November 23, 2022, wherein the exchanges were informed that the Resolution Professional filed an application before the Hon ble NCLT, Mumbai for approval of the resolution plan under Section 30(6) of the Insolvency and Bankruptcy Code, 2016, and pursuant to the provisions of Regulation 30(7) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform and update that in the above mentioned application, the Hon ble NCLT, Mumbai reserved its orders. A copy of the order of Hon ble NCLT, Mumbai dated April 12,

Sharon Bio-Medicine Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015

SHARONBIO: The Exchange had sought clarification from Sharon Bio-Medicine Limited with respect to announcement dated 18-Feb-2023, regarding strikes/lockouts/disturbances. On basis of above the Company was required to clarify following: 1. In the event of settlement of the proceedings, details of such settlement including - terms of the settlement, compensation/penalty paid (if any) and impact of such settlement on the financial position of the listed entity.The response of the Company is attached.

SHARONBIO:The Exchange has sought clarification from Sharon Bio-Medicine Limited with respect to announcement dated 27-Feb-2023, regarding fire accident at the Company's manufacturing unit located at M/s Sharon Bio-Medicine Limited, Plot No L6, MIDC Area, Taloja , Panvel, Dist: Raigad, Maharashtra. On basis of above the Company is required to clarify following:��1. Insurance amount claimed and realized by the listed entity for the loss/damage;2. The actual amount of damage caused due to the natural calamity or other force majeure events;3. Details of steps taken to restore normalcy and the imp

Sharon Bio-Medicine Limited has informed the Exchange regarding 'Disclosure of events or information pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015'.

Sharon Bio-Medicine Limited has informed the Exchange regarding 'Pursuant to Regulation 30 (4) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with Para B of Part A of Schedule III, this is to inform you that a fire accident took place during the morning hours on Sunday, February 26, 2023, at the Company s manufacturing unit located at M/s Sharon Bio-Medicine Limited, Plot No L6, MIDC Area, Taloja , Panvel, Dist: Raigad, Maharashtra '.

Sharon Bio-Medicine Limited has informed the Exchange regarding ''.

SHARONBIO: The Exchange has sought clarification from Sharon Bio-Medicine Limited with respect to announcement dated 18-Feb-2023, regarding strikes/lockouts/disturbances. On basis of above the Company is required to clarify following: 1. In the event of settlement of the proceedings, details of such settlement including - terms of the settlement, compensation/penalty paid (if any) and impact of such settlement on the financial position of the listed entity.The response of the Company is awaited.

Sharon Bio-Medicine Limited has informed the Exchange about strikes/lockouts/disturbances

Sharon Bio-Medicine Limited has informed the Exchange about Copy of Newspaper Publication Pursuant to Regulation 30 and 47 of the Listing Obligations and Disclosure Requirements Regulations, 2015 (LODR), please find enclosed the copies of Newspaper advertisement published on February,11th, 2023 given in Free Press Journal and Navshakti on the Unaudited Financial Results of the Company for the quarter and nine months ended December, 30, 2022

Sharon Bio-Medicine Limited has submitted to the Exchange, the financial results for the period ended December 31, 2022.

Ref: Corporate Announcement dated January 24, 2023Dear Sir/Madam,In furtherance to the Corporate Announcement dated January 24, 2023 pertaining to appointmentof Ms. Rakhi Makhloga as Whole time Company Secretary and Compliance Officer of theCompany, details as required under Regulation 30 of the SEBI (Listing Obligation andDisclosure Requirements) Regulations, 2015 read with SEBI CircularNo.CIR/CFO/CMD/4/2015 dated September 09, 2015, are enclosed herewith as Annexure I.This is for your information and records.

Sharon Bio-Medicine Limited has informed the Exchange regarding Appointment of Ms Rakhi Makhloga as Company Secretary & Compliance Officer of the company w.e.f. January 23, 2023.

Sharon Bio-Medicine Limited has informed the Exchange regarding 'With reference to the above referred subject, we are enclosing herewith the Confirmation Certificate dated January 6, 2023 received from M/s. Link Intime India Private Limited, the Registrar and Share Transfer Agent of our Company for the quarter ended December 31, 2022.'.

Sharon Bio-Medicine Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015

Sharon Bio-Medicine Limited has informed the Exchange about strikes/lockouts/disturbances

SHARONBIO: The Company is in receipt of advisory letters from NSE and BSE on December 12, 2022, and December 20, 2022, respectively. It is through the advisory letters that the Company noticed the mistake that it had inadvertently missed mentioning the names of the promoters corresponding to their shareholding in the shareholding patterns filed for the quarters ended December 2020 to September 2022. Immediately upon the receipt of the advisory letters, the Company rectified the same by disclosing the names of the promoters and submitted the updated shareholding patterns to the stock exchanges

Sharon Bio-Medicine Limited has informed the Exchange regarding 'Response to letter received on December 12, 2022 regarding non-compliance withSEBI (Listing Obligation and Disclosure Requirements) Regulation 2015 ( LODR Regulation )'.

Revised Shareholding Pattern from the quarter ended December 2020 to September 2022.

Response to your mail dated 17th November 2022 in the matter of Sharon Bio-Medicine Limited

Sub: Update on filing of the plan approval application in the matter of Sharon Bio-Medicine LimitedPursuant to the intimation dated 22nd November 2022, wherein we have informed that the Committee of Creditors(CoC) of Sharon Bio-Medicine Limited has approved the resolution plan with requisite majority as per Section 30(4)of the IBC, 2016. Kindly note that the undersigned has filed the plan approval application under Section 30(6) of theInsolvency and Bankruptcy Code, 2016 with the Hon���ble NCLT, Mumbai on 21st November 2022.Kindly take the same on your records

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform that the Committee of Creditors (CoC) of Sharon Bio-Medicine Limited has approved the resolution plan with requisite majority as per Section 30(4) of the IBC, 2016. Subsequently, the COC approved resolution plan has been filed with Hon'ble National Company Law Tribunal, Mumbai Bench on 22nd November, 2022 for its approval in accordance with Section 30(6) of the IBC, 2016.

Sharon Bio-Medicine Limited has informed the Exchange about update on committee of creditors meeting

Newspaper Publication of Audited Financial Results

Un-audited Financial Results for the quarter and half year ended September 30, 2022

Sharon Bio-Medicine Limited has informed the Exchange about Certificate under Regulation 74 (5) of Securities and Exchange Board of India (Depositories and Participants) Regulations 2018

Sharon Bio-Medicine Limited has informed the Exchange about update on committee of creditors meeting

Sharon Bio-Medicine Limited has informed the Exchange about resignation of Komal Mota as Company Secretary of the company w.e.f. 03-Oct-2022

Sharon Bio-Medicine Limited has informed the Exchange about Closure of trading window

Sharon Bio-Medicine Limited has informed the Exchange about update on corporate insolvency resolution process

Sharon Bio-Medicine Limited has informed the Exchange about update on committee of creditors meeting

Sharon Bio-Medicine Limited has informed the Exchange about update on committee of creditors meeting

Sharon Bio-Medicine Limited has informed the Exchange about update on corporate insolvency resolution process

Sharon Bio-Medicine Limited has informed the Exchange about Newspaper Advertisements

Sharon Bio-Medicine Limited has informed the Exchange about Board Meeting held on 12-Aug-2022 to consider financial statements for the period ended June 2022

Sharon Bio-Medicine Limited has informed the Exchange about update on corporate insolvency resolution process